|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Moexipril#Adult Indications and Dosage]] |
| {{Moexipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Moexipril HCl and Hydrochlorothiazide Tablets is indicated for treatment of patients with [[hypertension]]. This fixed combination is not indicated for the initial therapy of hypertension.
| |
| | |
| In using Moexipril HCl and [[Hydrochlorothiazide Tablets]], consideration should be given to the fact that another ACE inhibitor, [[captopril]], has caused [[agranulocytosis]], particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that Moexipril HCl and [[Hydrochlorothiazide]] Tablets does not have a similar risk. In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of [[angioedema]] in black than in nonblack patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, COATED [PADDOCK LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c657e39-edeb-4fa1-9a67-78eed3702494 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |